Tryptamine Therapeutics (ASX:TYP) Total Liabilities : A$0.37 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Total Liabilities?

Tryptamine Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was A$0.37 Mil.

Tryptamine Therapeutics's quarterly Total Liabilities declined from Dec. 2022 (A$2.73 Mil) to Jun. 2023 (A$1.75 Mil) and declined from Jun. 2023 (A$1.75 Mil) to Dec. 2023 (A$0.37 Mil).

Tryptamine Therapeutics's annual Total Liabilities increased from Jun. 2021 (A$2.59 Mil) to Jun. 2022 (A$4.81 Mil) but then declined from Jun. 2022 (A$4.81 Mil) to Jun. 2023 (A$1.75 Mil).

Tryptamine Therapeutics Total Liabilities Historical Data

The historical data trend for Tryptamine Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Total Liabilities Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

0.28

1.53

2.59

4.81

1.75

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial						3.34	4.81	2.73	1.75	0.37

Tryptamine Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tryptamine Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.714	+	(0	+	3.4694469519536E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.04)
	=	1.75

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	5.881	-	4.127
	=	1.75

Tryptamine Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.341	+	(0	+	0.027
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.37

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	3.083	-	2.715
	=	0.37

Tryptamine Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines